In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
List view / Grid view
Researchers pinpoint connections of risk variants with microglia functions that are important for Alzheimer’s disease (AD).
Researchers have found that targeting chimeras with click-release proteolysis activates specific molecules that target cancer cells without harming health cells.
This ebook outlines Euretos’ approach to target discovery and indication expansion.
Some individuals may experience more severe symptoms when infected with the same virus compared to others. The reasons behind this variability are not yet fully understood. While viral factors, such as differences in the virus strain, do play a role, they cannot account for the diverse responses observed among individuals…
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
Researchers from Tokyo Tech's World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum.
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.